Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BEAM-201 |
Synonyms | |
Therapy Description |
BEAM-201 comprises allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD7 and to harbor mutations in TRAC, CD7, CD52, and PDCD1, which potentially induces killing of tumor cells expressing CD7 (Blood (2024) 144 (Supplement 1): 4838, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BEAM-201 | BEAM 201|BEAM201 | BEAM-201 comprises allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD7 and to harbor mutations in TRAC, CD7, CD52, and PDCD1, which potentially induces killing of tumor cells expressing CD7 (Blood (2024) 144 (Supplement 1): 4838, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05885464 | Phase Ib/II | BEAM-201 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | Active, not recruiting | USA | 0 |